{"id":17727,"date":"2015-09-17T00:00:00","date_gmt":"2015-09-17T00:00:00","guid":{"rendered":"https:\/\/cadca1stg.wpengine.com\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/"},"modified":"2015-09-17T00:00:00","modified_gmt":"2015-09-17T00:00:00","slug":"fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products","status":"publish","type":"resource","link":"https:\/\/www.cadca.org\/pt\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/","title":{"rendered":"FDA emite ordens que interromper\u00e3o a venda e distribui\u00e7\u00e3o nos EUA de quatro produtos de cigarros da RJ Reynolds Tobacco Company"},"content":{"rendered":"<p>Esta semana, a Food and Drug Administration dos EUA emitiu ordens que interromper\u00e3o a venda e distribui\u00e7\u00e3o de quatro produtos de cigarros da RJ Reynolds Tobacco Company atualmente comercializados - incluindo sua marca Camel Crush Bold - porque os envios da empresa para esses produtos n\u00e3o atenderam aos requisitos estabelecidos na Lei Federal de Alimentos, Medicamentos e Cosm\u00e9ticos (Lei FD&amp;C).<\/p>\n<p>A avalia\u00e7\u00e3o da FDA constatou que os cigarros Camel Crush Bold, Pall Mall Deep Set Recessed Filter, Pall Mall Deep Set Recessed Filter Menthol e Vantage Tech 13 n\u00e3o eram substancialmente equivalentes (NSE) aos seus respectivos produtos &quot;predicados&quot; (ou seja, produtos que eram comercializados a partir de 15 de fevereiro de 2007) conforme identificado pelo fabricante. Mais especificamente, a ag\u00eancia concluiu que os produtos t\u00eam caracter\u00edsticas diferentes dos produtos predicados e que o fabricante falhou em mostrar que os novos produtos n\u00e3o levantam quest\u00f5es de sa\u00fade p\u00fablica diferentes quando comparados a eles. Consequentemente, neste momento, esses produtos n\u00e3o podem mais ser vendidos, distribu\u00eddos, importados ou comercializados no com\u00e9rcio interestadual.<\/p>\n<p>\u201cEssas decis\u00f5es foram baseadas em uma rigorosa revis\u00e3o baseada na ci\u00eancia projetada para proteger o p\u00fablico dos danos causados pelo uso do tabaco\u201d, disse Mitch Zeller, JD, diretor do Centro de Produtos de Tabaco da FDA, em um comunicado \u00e0 imprensa. \u201cA ag\u00eancia continuar\u00e1 analisando as submiss\u00f5es de produtos e exercendo sua autoridade legal e dever de prote\u00e7\u00e3o ao consumidor para remover produtos do mercado quando eles n\u00e3o atenderem aos requisitos de sa\u00fade p\u00fablica estabelecidos por lei.\u201d<\/p>\n<p>Os produtos que receberam pedidos de NSE entraram no mercado durante um per\u00edodo provis\u00f3rio estabelecido pela Lei de Preven\u00e7\u00e3o ao Fumo Familiar e Controle do Tabaco de 2009. Como parte do per\u00edodo provis\u00f3rio, a empresa teve que enviar um pedido de equival\u00eancia substancial (SE) ao FDA at\u00e9 22 de mar\u00e7o , 2011, para que os produtos permane\u00e7am no mercado. A FDA analisa as submiss\u00f5es de produtos sob este caminho para determinar se o produto \u00e9 substancialmente equivalente a um produto predicado v\u00e1lido. Entre outras raz\u00f5es, se uma empresa n\u00e3o fornecer as informa\u00e7\u00f5es necess\u00e1rias para mostrar que seu produto \u00e9 substancialmente equivalente a um produto predicado v\u00e1lido, o FDA tem autoridade para encontrar um produto n\u00e3o substancialmente equivalente.<\/p>\n<p>A base cient\u00edfica para essas quatro decis\u00f5es inclui uma falha em demonstrar que o aumento do rendimento de constituintes nocivos ou potencialmente nocivos, n\u00edveis mais altos de mentol e\/ou a adi\u00e7\u00e3o de novos ingredientes nos produtos atualmente comercializados<strong>\u2013\u00a0<\/strong>quando comparado com os produtos predicados\u00a0<strong>\u2013\u00a0<\/strong>n\u00e3o levantam quest\u00f5es diferentes de sa\u00fade p\u00fablica.<\/p>\n<p>No caso do Camel Crush Bold, a falha em demonstrar que a adi\u00e7\u00e3o de uma c\u00e1psula de mentol no filtro n\u00e3o afetou a percep\u00e7\u00e3o e o uso do consumidor tamb\u00e9m contribuiu para a decis\u00e3o.<\/p>\n<p>Quando o FDA emite um pedido NSE, o produto de tabaco em estoque, inclusive em um local de varejo, torna-se adulterado e com marca incorreta. Como resultado, \u00e9 ilegal vender ou distribuir o produto no com\u00e9rcio interestadual, ou vender ou distribuir o produto recebido do com\u00e9rcio interestadual. Fazer isso pode fazer com que o FDA inicie uma a\u00e7\u00e3o de execu\u00e7\u00e3o, incluindo apreens\u00e3o, sem aviso pr\u00e9vio.<\/p>\n<p>Reconhecendo que os varejistas podem ter op\u00e7\u00f5es limitadas para descartar produtos em seus estoques atuais, o FDA n\u00e3o pretende tomar medidas de execu\u00e7\u00e3o por 30 dias em produtos adquiridos anteriormente que um varejista tenha em seu estoque. Esta pol\u00edtica \u00e9 descrita em uma orienta\u00e7\u00e3o finalizada recentemente. \u00c9 importante ressaltar que a pol\u00edtica n\u00e3o se aplica a estoques adquiridos por varejistas ap\u00f3s a data do pedido. Os varejistas s\u00e3o incentivados a entrar em contato com seu fornecedor ou fabricante para discutir poss\u00edveis op\u00e7\u00f5es para os estoques existentes em locais espec\u00edficos do varejista.<\/p>\n<p>O descumprimento das leis federais sobre produtos de tabaco pode resultar no in\u00edcio de outras a\u00e7\u00f5es da FDA sem aviso pr\u00e9vio, incluindo, mas n\u00e3o limitado a, penalidades civis em dinheiro, ordens de proibi\u00e7\u00e3o de venda de tabaco, processo criminal, apreens\u00e3o e\/ou liminar.<\/p>\n<p>Os consumidores e outras partes interessadas podem relatar uma poss\u00edvel viola\u00e7\u00e3o da Lei FD&amp;C relacionada ao tabaco, incluindo a venda ou distribui\u00e7\u00e3o cont\u00ednua dos quatro produtos nos Estados Unidos, usando o FDA\u00a0<a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/ptvr\/index.cfm\" target=\"_blank\" rel=\"noopener\">Formul\u00e1rio de Den\u00fancia de Potencial Viola\u00e7\u00e3o de Produtos de Tabaco<\/a>.<\/p>\n<p><strong>VEJA TAMB\u00c9M: <\/strong><\/p>\n<p><a href=\"https:\/\/www.geohealthequity.org\/\" target=\"_blank\" rel=\"noopener\">Kit de ferramentas on-line da CADCA para prevenir o uso de tabaco<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>This week, the U.S. Food and Drug Administration issued orders that will stop the further sale and distribution of four<\/p>","protected":false},"author":23,"featured_media":0,"template":"","resource_type":[281],"drug_specific_issues":[296],"action_to_do":[],"class_list":["post-17727","resource","type-resource","status-publish","hentry","resource_type-coalitions-online","drug_specific_issues-tobacco"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products | CADCA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cadca.org\/pt\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products | CADCA\" \/>\n<meta property=\"og:description\" content=\"This week, the U.S. Food and Drug Administration issued orders that will stop the further sale and distribution of four\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cadca.org\/pt\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/\" \/>\n<meta property=\"og:site_name\" content=\"CADCA\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/cadca-member-of-logo1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"880\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\\\/\",\"url\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\\\/\",\"name\":\"FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products | CADCA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cadca.org\\\/#website\"},\"datePublished\":\"2015-09-17T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\\\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cadca.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cadca.org\\\/#website\",\"url\":\"https:\\\/\\\/www.cadca.org\\\/\",\"name\":\"CADCA\",\"description\":\"The Premier Prevention Association\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cadca.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products | CADCA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cadca.org\/pt\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/","og_locale":"pt_PT","og_type":"article","og_title":"FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products | CADCA","og_description":"This week, the U.S. Food and Drug Administration issued orders that will stop the further sale and distribution of four","og_url":"https:\/\/www.cadca.org\/pt\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/","og_site_name":"CADCA","og_image":[{"width":880,"height":500,"url":"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/cadca-member-of-logo1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tempo estimado de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cadca.org\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/","url":"https:\/\/www.cadca.org\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/","name":"FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products | CADCA","isPartOf":{"@id":"https:\/\/www.cadca.org\/#website"},"datePublished":"2015-09-17T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.cadca.org\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cadca.org\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.cadca.org\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cadca.org\/"},{"@type":"ListItem","position":2,"name":"FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products"}]},{"@type":"WebSite","@id":"https:\/\/www.cadca.org\/#website","url":"https:\/\/www.cadca.org\/","name":"CADCA","description":"The Premier Prevention Association","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cadca.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"}]}},"_links":{"self":[{"href":"https:\/\/www.cadca.org\/pt\/wp-json\/wp\/v2\/resource\/17727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cadca.org\/pt\/wp-json\/wp\/v2\/resource"}],"about":[{"href":"https:\/\/www.cadca.org\/pt\/wp-json\/wp\/v2\/types\/resource"}],"author":[{"embeddable":true,"href":"https:\/\/www.cadca.org\/pt\/wp-json\/wp\/v2\/users\/23"}],"version-history":[{"count":0,"href":"https:\/\/www.cadca.org\/pt\/wp-json\/wp\/v2\/resource\/17727\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.cadca.org\/pt\/wp-json\/wp\/v2\/media?parent=17727"}],"wp:term":[{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/www.cadca.org\/pt\/wp-json\/wp\/v2\/resource_type?post=17727"},{"taxonomy":"drug_specific_issues","embeddable":true,"href":"https:\/\/www.cadca.org\/pt\/wp-json\/wp\/v2\/drug_specific_issues?post=17727"},{"taxonomy":"action_to_do","embeddable":true,"href":"https:\/\/www.cadca.org\/pt\/wp-json\/wp\/v2\/action_to_do?post=17727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}